Liquid chromatography and mass spectrometry instrument system

液相色谱、质谱仪器系统

• 批准号: 10415617
• 负责人: Francis Michael Sverdrup
• 金额: $ 24.95万
• 依托单位: SAINT LOUIS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10415617
• 关键词: Aging; Award; Biological Response Modifier Therapy; Central Nervous System Diseases; Communicable Diseases; Computer Workstations; Computer software; Consultations; Core Facility; Data; Data Analyses; Disease; Drug Kinetics; Ensure; Funding; Future; Genetic Diseases; Hepatitis B; Immunology; Institutes; Laboratories; Legal patent; Liquid Chromatography; Liver diseases; Lysosomal Storage Diseases; Malignant Neoplasms; Measures; Microbiology; Molecular; Muscular Dystrophies; Mycoses; Nitrogen; Performance; Pharmaceutical Preparations; Pharmacology; Program Development; Publications; Request for Applications; Research; Research Personnel; Saints; Services; Speed; Supervision; System; Technology; Testing; Time; Tuberculosis; United States National Institutes of Health; Universities; chronic pain; clinical translation; drug development; drug discovery; improved; in vitro Assay; in vivo; innovation; instrument; instrumentation; liquid chromatography mass spectrometry; mass spectrometer; member; neglect; repaired; success; time use

This instrument application requests funds to purchase a liquid chromatography (LC) / mass spectrometry (MS) system comprised of a SCIEX 4500 triple stage quadrupole (TSQ) mass spectrometer, Exion AC LC and autosampler, Peak nitrogen generator, and workstation computer. The proposed instrument will be housed in in the Saint Louis University (SLU) Department of Molecular Microbiology & Immunology and will be managed as a critical asset of the ADME/PK Core Services Group of the SLU Institute for Drug and Biotherapeutic Innovation (IDBI). This core offers access to expert pharmacology-related consultations and wet bench support to the more than 140 IDBI members engaged in drug discovery for diseases such as cancer; chronic pain; central nervous system disorders; liver disease; infectious diseases such as hepatitis B, tuberculosis, and fungal infections; genetic disorders including muscular dystrophy and lysosomal storage disease; and neglected diseases. Laboratory support is critically dependent on having functional and reliable tandem LC/MS instrument technology to perform the in vitro assays and in vivo studies that are commonly employed in the testing funnels of nearly every drug development program. Performance of these functions is currently dependent on an aging Sciex 4000 instrument system which has been in use for more than 14 years. Not only is it becoming more difficult to maintain and repair each year, but it also lacks the sensitivity, speed, and other improved technical specifications provided by newer redesigned instrument systems. The Sciex 4500 also comes with upgraded software platforms for acquiring and analyzing data. Thus, our primary needs for the Sciex 4500 instrument system are to ensure continuity and stability and to provide enhanced performance in support of the ongoing and future needs of our many users, knowing that our current instrument is approaching a time when it will no longer be serviceable. The university has made a strong commitment to the strategy of helping its researchers obtain key pharmacokinetic data as evidenced by the recent hiring of a highly skilled full time doctoral level analytical chemist, Dr. Abdul Mottaleb, who has extensive expertise using LC/MS to detect a wide variety of analytes. He is supervised by Dr. Griggs, the PI of this application, who is the Director of the core facility and a co-Director of the SLU IDBI. This application summarizes drug discovery research of 11 users of the current instrument system who will have an ongoing need for accurate and timely high-quality data from the new instrument. This includes four major users with a combined 7 active NIH awards that are expected to require over 60% of the instrument’s authorized usage time (AUT). The SLU-IDBI continues to promote ADME/PK services to new users to maximize their impact measured through increased publications, patents, and clinical translation of academic research. This new instrumentation system will ensure continued success of the important facility for the next 10 years.

该仪器申请要求资金购买液相色谱（LC）/质谱仪 (MS)系统由SCIEX 4500三级四极杆（TSQ）质谱仪、Exion AC LC和 自动进样器、峰值氮气发生器和工作站计算机。拟议的仪器将安装在 在圣刘易斯大学（SLU）分子微生物学和免疫学系，并将管理 作为SLU药物和生物制剂研究所ADME/PK核心服务组的重要资产 创新（IDBI）。这个核心提供了获得专家药理学相关的咨询和湿台 支持140多个IDBI成员从事药物发现的疾病，如癌症;慢性 疼痛;中枢神经系统疾病;肝脏疾病;传染性疾病，如B型肝炎、结核病，以及 遗传性疾病，包括肌营养不良症和溶酶体贮积病;和 被忽视的疾病实验室支持主要依赖于具有功能和可靠的串联 LC/MS仪器技术，用于进行体外测定和体内研究，这些测定和研究通常用于 几乎所有药物研发项目的测试漏斗这些职能的履行目前 依赖于已使用超过14年的老化Sciex 4000仪器系统。不仅 它是越来越难以维护和维修，每年，但它也缺乏灵敏度，速度，和其他 新的重新设计的仪器系统提供了改进的技术规格。Sciex 4500还 配备了用于获取和分析数据的升级软件平台。因此，我们的主要需求是 Sciex 4500仪器系统是为了确保连续性和稳定性， 支持我们的许多用户的当前和未来需求，知道我们目前的仪器正在接近 到时候它就不能再用了该大学已作出了坚定的承诺，以战略， 帮助其研究人员获得关键的药代动力学数据，最近聘请了一位高技能的全职 时间博士水平的分析化学家，阿卜杜勒Mottaleb博士，谁拥有广泛的专业知识，使用LC/MS检测 多种分析物。他由本申请的PI Griggs博士监督，Griggs博士是 核心设施和SLU IDBI的共同主任。本申请总结了11个药物发现研究 目前仪器系统的用户，他们将持续需要准确和及时的高质量数据 新的工具。这包括四个主要用户，共有7个活跃的NIH奖项， 预计需要超过60%的仪器授权使用时间（AUT）。SLU-IDBI继续 向新用户推广ADME/PK服务，通过增加出版物，最大限度地扩大其影响， 专利和学术研究的临床翻译。这一新的仪器系统将确保 未来10年的重要设施。